Huadong Medicine's Subsidiary Receives NMPA Approval to Initiate Clinical Trials of DR30206 for Advanced Solid Tumors

Huadong Medicine announced on June 29 that on June 28, its holding subsidiary Zhejiang Doer Biologics Co., Ltd. (hereinafter referred to as "Doer Biologics") received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The clinical trial application for the injectable DR30206 submitted by Doer Biologics has been approved, allowing the product to proceed with clinical trials for advanced solid tumors. Injectable DR30206 is a Class 1 therapeutic biologic independently developed by Doer Biologics and possesses global intellectual property rights.